Ranjeeta Sinvhal

Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices.

Journal: Pharmaceutical medicine

Published: November 26, 2025

Publisher Correction: Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies.

Journal: Therapeutic innovation & regulatory science

Published: August 10, 2025

Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies.

Journal: Therapeutic innovation & regulatory science

Published: October 16, 2024

A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.

Journal: Dermatology and therapy

Published: July 13, 2024

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials.

Journal: Dermatology and therapy

Published: June 14, 2024

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.

Journal: Anais brasileiros de dermatologia

Published: June 06, 2024

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.

Journal: Journal of the American Academy of Dermatology

Published: March 28, 2023

Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.

Journal: British journal of clinical pharmacology

Published: March 03, 2023

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

Journal: The British journal of dermatology

Published: October 14, 2021

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

Journal: The British journal of dermatology

Published: June 17, 2021

Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.

Journal: Journal of the American Academy of Dermatology

Published: November 10, 2020

Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices.

Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices.

Publisher Correction: Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies.

Publisher Correction: Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies.

Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies.

Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies.

A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.

A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials.

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials.

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.

Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.

Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.

Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.